These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 38439728)

  • 21. [Juvenile pemphigus vulgaris].
    Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
    Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose rituximab as an adjuvant therapy in pemphigus.
    Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
    Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option.
    Schauer F; Ishii N; Mockenhaupt M; Bruckner-Tuderman L; Hashimoto T; Kiritsi D
    Front Immunol; 2019; 10():3116. PubMed ID: 32038636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.
    Mimouni D; Blank M; Payne AS; Anhalt GJ; Avivi C; Barshack I; David M; Shoenfeld Y
    Clin Exp Immunol; 2010 Dec; 162(3):543-9. PubMed ID: 20964642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.
    Nagel A; Podstawa E; Eickmann M; Müller HH; Hertl M; Eming R
    J Invest Dermatol; 2009 Sep; 129(9):2202-10. PubMed ID: 19282839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris.
    Sinistro A; Calabresi V; Lupi F; Sera F; Frezzolini A; Ruffelli M; De Pità O; Camaioni D; Cianchini G; Di Zenzo G
    Eur J Dermatol; 2015; 25(6):578-85. PubMed ID: 26552329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemphigus patients with initial negative levels of anti-desmoglein: A subtype with different profile?
    Balighi K; Ashtar Nakhaei N; Daneshpazhooh M; Aryanian Z; Aslani S; Balighi S; Azizpour A
    Dermatol Ther; 2022 Apr; 35(4):e15299. PubMed ID: 34981632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
    Spałek MM; Jałowska M; Bowszyc-Dmochowska M; Dmochowski M
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399557
    [No Abstract]   [Full Text] [Related]  

  • 29. Pemphigus: Current and Future Therapeutic Strategies.
    Didona D; Maglie R; Eming R; Hertl M
    Front Immunol; 2019; 10():1418. PubMed ID: 31293582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
    Colliou N; Picard D; Caillot F; Calbo S; Le Corre S; Lim A; Lemercier B; Le Mauff B; Maho-Vaillant M; Jacquot S; Bedane C; Bernard P; Caux F; Prost C; Delaporte E; Doutre MS; Dreno B; Franck N; Ingen-Housz-Oro S; Chosidow O; Pauwels C; Picard C; Roujeau JC; Sigal M; Tancrede-Bohin E; Templier I; Eming R; Hertl M; D'Incan M; Joly P; Musette P
    Sci Transl Med; 2013 Mar; 5(175):175ra30. PubMed ID: 23467561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Delays for Non-melanoma Skin Cancers in Renal Transplant Recipients during the COVID-19 Pandemic: What is Hiding Behind the Mask?
    Mokos M; Bašić-Jukić N
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):111-113. PubMed ID: 34477079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
    Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
    Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
    Lancman G; Mascarenhas J; Bar-Natan M
    J Hematol Oncol; 2020 Oct; 13(1):131. PubMed ID: 33008453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab.
    Albers LN; Liu Y; Bo N; Swerlick RA; Feldman RJ
    J Am Acad Dermatol; 2017 Dec; 77(6):1074-1082. PubMed ID: 28927663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
    N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
    Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
    Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.